Navigation Links
Mast Therapeutics Reports First Quarter 2013 Financial Results
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the quarter ended March 31, 2013.

Brian M. Culley , Chief Executive Officer, said: "We have opened more than a dozen clinical sites in EPIC, our pivotal phase 3 study in sickle cell disease, and are on track to meet our goal of opening approximately 40 U.S. sites by year-end.  We also plan to support U.S. enrollment by opening roughly 30 sites outside the U.S., beginning early next year.  Mast remains the only company with a new drug in phase 3 development in sickle cell disease and investigators have been enthusiastic about the potential for MST-188 to become the first agent approved to treat an on-going vaso-occlusive crisis of sickle cell disease."

First Quarter 2013 Operating ResultsThe Company's net loss for the first quarter of 2013 was $5.6 million, or $0.12 per share (basic and diluted), compared to a net loss of $4.2 million, or $0.09 per share (basic and diluted), for the same period in 2012.

Research and development (R&D) expenses for the first quarter of 2013 were $3.4 million, an increase of $1.2 million, or 56%, compared to $2.2 million for the same period in 2012. The increase was primarily due to increases of $2.0 million in external clinical study fees and expenses and $0.2 million in personnel costs, offset by a $1.0 million decrease in external nonclinical study fees and expenses.  The increase in external clinical study fees and expenses was primarily related to EPIC, the Company's phase 3 study of MST-188 in sickle cell disease, and its thorough QT/QTc study of MST-188 in healthy volunteers, both of which were initiated in the first quarter.  The decrease in external nonclinical study fees and expenses resulted primarily from a decrease in research-related manufacturing expenses for ANX-514, which the Company discontinue
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... National Institute of,Standards and Technology (NIST) has selected ... Commerce Department,s Advanced Technology Program,(ATP), a peer-reviewed competition. ... the early-phase Michigan biotechnology company developing,drug therapies to ... disorders. Velcura scientists have discovered a family ...
... YORK, Sept. 27 Immtech Pharmaceuticals,Inc. (Immtech) (Amex: ... Food and Drug,Administration of the People,s Republic of ... for conducting a Phase III clinical,trial with pafuramidine, ... Pneumocystis pneumonia (PCP). Pafuramidine is among the first,drugs ...
Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Chinese SFDA Grants Immtech Fast Track Status 2Chinese SFDA Grants Immtech Fast Track Status 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving ... according to new research from The University of ... National guidelines state that health care professionals (HCPs) ... a healthy weight. Firefighters have high rates of ... of line-of-duty deaths in firefighters. This study assessed ...
(Date:7/11/2014)... The Corn Farming industry ... on the heels of fresh biofuel demand. The Federal ... a larger share of their farmland to cultivating high-value ... required the mixing of 5.0% renewable content in gasoline ... United States created a key export market for Canadian ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
(Date:7/11/2014)... Riverside Health System became the first provider ... in late 2012 and now, in partnership with Williamsburg Landing, ... the Williamsburg and Newport News region. , Also known as ... to independent older adults who wish to remain in their ... of continuing care services as well as control over the ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... not quintessentially masculine, women in their fertile phase are ... women paired with George Clooney types. But women ... to their partners, a recent study co-authored by a ... a man,s intelligence has no effect on the extent ...
... Residents of Cuyahoga County, and later Lorain County, will ... of a national resource for childhood growth and development. ... of children,s health ever conducted in the United States. ... The study will enroll women who are pregnant ...
... -- People over age 65 are at increased risk for ... study finds. Latent tuberculosis occurs when TB bacteria lurk ... has no symptoms of TB and is not contagious. However, ... cause tuberculosis, which can be fatal if it goes untreated. ...
... has received a boost from a surprising source: the 2009 ... 2009 H1N1 strain developed antibodies that are protective against a ... Medicine and the University of Chicago have found. The results ... Medicine . "Our data shows that infection with the ...
... one of today,s most exciting scientific and clinical areas. ... rulings by regulatory bodies or ethical controversies. These often ... ethicists, legislators, the media and the public. ESHRE,s ... of the world,s leading experts in reproductive medicine gather ...
... Race and ethnicity play major roles in whether people get ... much less likely to undergo colonoscopies than white people. Now, ... people live. Research by oncologist Dr. Thomas Semrad ... Center found that location makes a big difference in rates ...
Cached Medicine News:Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Case Western Reserve University School of Medicine launches the National Children's Study 2Health News:Treating Latent TB After 65 Raises Serious Side-Effect Risk 2Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: